debt_leverage_profile
Post-NuVasive merger, net debt ~$1.7B; leverage ~2.5x EBITDA; a 20bp rate rise adds ~$3.4M annual interest on variable-rate tranches
Inferred
Agent_Inference
interest_rate_sensitivity
~60% fixed-rate debt post-merger limits sensitivity; 20bp rise impacts ~$3-4M EBIT annually; manageable given ~$300M+ EBITDA run-rate
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
Titanium and cobalt-chrome sourcing concentrated in China/Russia; PEEK polymer components dependent on Southeast Asian specialty chemical suppliers
Inferred
Agent_Inference
international_expansion_readiness
Top-3 international markets: Europe (EUR), Japan (JPY), Australia (AUD); JPY depreciation (~15% YoY 2023) and EUR volatility create meaningful translation risk on ~30% international revenue
Inferred
Agent_Inference
geographic_footprint
~70% US revenue, ~30% international; EUR, JPY, AUD exposure; hedging programs partial; currency headwinds reduced international reported revenue ~2-3% in recent years
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
No single vendor >30% of input cost publicly disclosed; titanium rod/bar suppliers and ERP systems (SAP) create moderate non-substitutable dependency risk
Inferred
Agent_Inference
business_model_type_primary
Cloud dependency low; core operations rely on proprietary manufacturing and hospital sales force; AWS/Azure termination would disrupt analytics/ERP, not core product delivery
Inferred
Agent_Inference
business_model_type_secondary
Secondary digital tools (surgical planning software, Excelsius GPS robotics platform) have cloud components; 30-day termination would impair software-assisted surgery workflows
Inferred
Agent_Inference
switching_cost_profile
Moderate-high API/software coupling via Excelsius GPS robotic system; hospitals integrating robotic workflows face significant re-training and capital switching costs
Inferred
Agent_Inference
howey_test_risk_index
Revenue model is product/service sales to hospitals; no investment contract or profit-sharing structure; Howey Test risk index: negligible/not applicable
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Handles limited patient data via surgical planning tools; GDPR exposure in EU markets moderate; CCPA exposure low; not a primary data processor, reducing headline compliance risk
Inferred
Agent_Inference
antitrust_exposure_flag
NuVasive merger (2023) created top-3 spine implant company; DOJ reviewed and cleared with conditions; ongoing pricing/bundling scrutiny in hospital contracting remains moderate risk
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
~85% transactional (implant and instrument sales per procedure); ~15% recurring via service contracts, robotics leases, and software subscriptions
Inferred
Agent_Inference
monetization_vector
Primary: per-procedure implant sales; secondary: capital equipment (Excelsius GPS) plus recurring software/service fees; razor-and-blade model emerging with robotics
Inferred
Agent_Inference
pricing_architecture
ASP pressure from GPO contracts and hospital value analysis committees; 2-4% annual price erosion typical; robotics platform helps defend pricing through procedural differentiation
Inferred
Agent_Inference
pricing_power_rating
Moderate; brand and clinical outcomes support premium pricing but GPO aggregation and competitive intensity from Medtronic/Stryker/Zimmer limit unilateral price increases; rating: 5.5/10
Inferred
Agent_Inference
target_gross_margin_bracket
34.7% Gross Margin (Moderate (20-40%))
High
SEC-XBRL
churn_vulnerability_index
No meaningful free-rider problem; implant consumption requires purchase; surgeon loyalty programs and instrument sets create moderate lock-in; churn risk low once robotic platform adopted
Inferred
Agent_Inference
headcount_cost_structure
Revenue growth is headcount-sublinear post-NuVasive merger synergies; sales force productivity improvements and robotics enable ~10-15% revenue growth with <5% headcount growth
Inferred
Agent_Inference
marginal_cost_of_growth
Manufacturing scale and combined NuVasive/Globus infrastructure yield declining marginal cost; estimated 60-65% gross margin suggests strong incremental contribution on new revenue
Inferred
Agent_Inference
franchise_compliance_risk
Not a franchise model; direct sales force and independent distributors used; distributor compliance drift (off-label promotion, kickback risk) is the analogous risk, historically moderate in spine
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, GPO dependency intensifies and surgeon coverage costs rise; estimated CAC ~$150-200K per new surgeon relationship; LTV/CAC ratio remains attractive at ~8-10x
Inferred
Agent_Inference
network_effect_present
Weak direct network effects; indirect effects via Excelsius GPS data improving surgical outcomes algorithms; proprietary robotic data moat builds over time but not yet defensively scaled
Inferred
Agent_Inference
asset_efficiency_ratio
11.4% Return on Assets (Excellent)
High
SEC-XBRL
recession_resistance_tier
Tier 2 (moderate resilience); spine surgery partially deferrable, causing 5-10% volume declines in recessions; essential procedures (trauma, severe deformity) sustain baseline demand
Inferred
Agent_Inference
customer_segment_primary
Spine and orthopedic surgeons at acute-care hospitals and ambulatory surgery centers; top-10 hospital systems likely represent <15% of revenue, limiting concentration risk
Inferred
Agent_Inference
customer_segment_secondary
Ambulatory surgery centers (ASCs) growing rapidly as shift from inpatient; ASC segment now ~30% of addressable volume and key growth driver for minimally invasive product lines
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
5.6% CapEx / Revenue (Moderate-CapEx)
High
SEC-XBRL
sec_cik
0001237831
High
SEC-EDGAR
ticker
GMED
High
SEC-EDGAR